|
|
APhA Moves Into New Headquarters
 
APhA has relocated back to our historic
headquarters on the National Mall. Our phone numbers and email
addresses remain the same, but our mailing address is now 2215
Constitution Ave. NW Washington, DC 20037. We anticipate some customer
service delays as we acclimate to our new offices, and appreciate your
continued understanding.
|
 Health Care Reform Hub
 Take
Action Now on Health Care Reform! Learn what’s happening, find
out what APhA is doing to get pharmacists a seat at the HCR table, and
get the scoop on how to share your story in the Health Care Reform Hub.
|
|
|
|
|
|
|
|
Current News
|
 ›› Modafinil’s effects on dopamine - Small pilot study shows that modafinil (Provigil—Cephalon) at therapeutic doses of 200 or 400 mg acutely blocked dopamine transporters and increased dopamine levels in the brain, effects that can potentially increase the abuse potential of this agent in vulnerable persons. |
| ›› Higher infliximab dose fails to improve clinical endpoints in patients with RA - A prospective trial in patients with rheumatoid arthritis (RA) who had an incomplete response to 1 year of infliximab (Remicade—Centocor) therapy concluded that increasing the dose of infliximab from 3 to 5 mg/kg given every 8 weeks for an additional year failed to significantly improve Disease Activity Score, number of swollen or tender joints, or laboratory values such as C-reactive protein or erythrocyte sedimentation rate. |
| ›› Repeat and higher-intensity smoking cessation interventions best - Repeated, intensive interventions consisting of pharmacotherapy, counseling, and continued dialogue with health providers are the most successful in helping patients quit smoking. |
Pharmacy Today Feature Articles
|
|
|
|
Shop
APhA